Tools
Hand, Foot, and Mouth Disease
Introduction
Hand, foot, and mouth disease (HFMD) is a common viral illness that usually affects infants and children but can also affect adults. The infection usually involves the hands, feet, mouth, and sometimes, even the genitals and buttocks. The cause of HFMD is coxsackievirus A type 16 in most cases, but many other strains of coxsackievirus can also cause the infection. See Image. Hand, Foot, and Mouth Disease. In the western Pacific, HFMD has been linked to enterovirus. The coxsackievirus is a member of the Picornaviridae family, which includes non-enveloped single-stranded RNA viruses.[1][2][3]
Etiology
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Etiology
HFMD is a viral exanthem, and the coxsackievirus of the Enterovirus family most commonly causes it. Coxsackievirus A16 and enterovirus A71 are the serotypes most commonly implicated as causative agents.[4][5][6] Coxsackievirus A6 has recently emerged as another cause of HFMD in the USA and worldwide.[7] Coxsackievirus A10 has been implicated in severe disease.[8] Coxsackievirus A4 to A7, A9, B1 to B3, and B5 have also been less commonly associated with HFMD.[9]
Epidemiology
This viral infection is not indigenous to 1 area in particular but occurs worldwide. Children (particularly those younger than 7 years of age) tend to be infected at a higher rate than adults, so you can see outbreaks in daycares, summer camps, or within the family. Large-scale surveillance from China demonstrated that more than 90% of HFMD cases occurred in children less than 5 years of age, mortality was around 0.03%, and that cases tended to occur more frequently during late spring and early summer.[10] A study from Vietnam showed a positive correlation between an increase in environmental temperature and humidity and an increase in the incidence of HFMD.[11] In 2021, French surveillance found a rapid increase in HFMD cases, with more than 3400 cases. Although more than 90% of sequenced cases were found to be linked to Enterovirus, atypical cases were found to be associated with Coxsackievirus A6 and A16.[12] Coxsackievirus A6 remains the dominant cause of HFMD in the United States.[7]
Pathophysiology
The spread of the human enterovirus is mediated by oral ingestion of the shed virus from infected hosts' gastrointestinal or upper respiratory tract or via vesicle fluid or oral secretions.[13] Patients tend to be most infectious in the first week of the disease, with an incubation period ranging between 3 to 6 days.[13] After ingestion, the virus replicates in the lower intestine and pharynx lymphoid tissue and spreads to the regional lymph nodes. This can be spread to multiple organs, including the central nervous system, heart, liver, and skin.
History and Physical
HFMD can start with a low-grade fever, reduced appetite, and general malaise. The most common HFMD presenting symptom is usually mouth or throat pain secondary to the enanthem. A thin halo of erythema surrounds the presence of vesicles, eventually rupturing and forming superficial ulcers with a grey-yellow base and erythematous rim. The exanthem can be macular, papular, or vesicular. The lesions are about 2 mm to 6 mm in size, are non-pruritic, and are typically not painful. They last about 10 days, tend to rupture, and result in painless and shallow ulcers that do not leave a scar. The exanthem can involve the hand, feet, buttocks, legs, and arms dorsum. Oral lesions commonly involve buccal and tongue ulcers but may also involve the soft palate.[13] HFMD can also present with atypical features like concomitant aseptic meningitis. Enterovirus infections that cause HFMD are notorious for involving the central nervous system and may cause encephalitis, polio-like syndrome, acute transverse myelitis, Guillain-Barre syndrome, benign intracranial hypertension, and acute cerebellar ataxia.[13]
Evaluation
The diagnosis of HFMD is usually made clinically. The virus can be detected in the stool about 6 weeks after infection; however, shedding from the oropharynx is generally less than 4 weeks. Light microscopy of biopsies or scrapings of vesicles differentiates HFMD from varicella-zoster virus and herpes simplex virus. While serology is not sensitive to diagnosing HFMD, IgG levels can be used to monitor recovery. In some centers, serology is used to differentiate enterovirus 71 from coxsackievirus, as this has prognostic significance. Today, polymerase chain reaction assays are available in most centers to confirm the diagnosis of coxsackievirus. A swab of the lesion can detect coxsackievirus or enterovirus using real-time PCR assays.[14][7]
Treatment / Management
HFMD is a mild clinical syndrome and resolves within 7 to 10 days. Treatment is primarily supportive. Pain and fever can be managed with NSAIDs and acetaminophen. Making sure the patient remains well-hydrated is important. Additionally, a mixture of ibuprofen and diphenhydramine can be used to gargle, which helps coat the ulcers, easing the pain.[15][16] Steroids were found to increase the risk of severe HFMD.[17] Over the past decade, researchers have developed specific treatments to manage enterovirus 71-induced HFMD because of its severe neurological complications. So far, no drug has been approved, but promising novel agents include molecular decoys, translation inhibitors, receptor antagonists, and replication inhibitors. An antiviral agent that has shown promise in treating enterovirus 71 is pleconaril, an anti-picornaviral agent. However, there are currently no licensed antivirals for the treatment of HFMD.[18] Anecdotal reports have shown some clinical response to acyclovir, but large-scale trials have not established this.[19] Several vaccine candidates have been developed against HFMD and Enteroviruses. Strain-specific inactivated whole-virus aluminum-adjuvant vaccines have been developed in China and are approved for widespread use.[10] In a study with 10,077 participants, a 3-dose regimen of the EV71 C4a vaccine showed an overall efficacy of 94.7% (95% CI 87.8–97.6), with protection lasting around 2 years.[20] virus-like particles, DNA, peptide, and subunit vaccines have been developed but are in various stages of clinical trials.[21](A1)
Differential Diagnosis
The differential diagnosis for HFMD should include conditions that present with maculopapular or vesicular rashes with or without oral lesions. These conditions include:
- Erythema multiforme
- Herpangina
- Herpes simplex
- Herpes zoster
- Kawasaki disease
- Toxic epidermal necrolysis
- Viral pharyngitis
- Rocky Mountain spotted fever
- Varicella zoster infection (chickenpox)
- Steven-Johnson syndrome
- Monkeypox - In the context of an ongoing outbreak, it becomes important to consider the difficulty in clinically differentiating between monkeypox and HFMD [13][22]
Prognosis
The prognosis for most patients with HFMD is excellent. Most patients recover within a few weeks without any residual sequelae. Acute illness usually lasts 10 to 14 days, and the infection rarely recurs or persists. However, some patients with HFMD may develop serious complications, which include the following:
- Persistent stomatitis is associated with painful ulcers. The pain can be severe enough to limit food intake, and dehydration can result, especially in young children.
- Aseptic meningitis can occur, but this is more common with enterovirus 71. This particular virus is associated with a higher neurological involvement rate than coxsackievirus. The individual may develop acute cerebellar ataxia, polio-like syndrome, encephalitis, benign intracranial hypertension, and Guillain-Barre syndrome. The virus is believed to induce damage to the gray matter, resulting in motor dysfunction.[23]
- Coxsackievirus can rarely cause interstitial pneumonia, myocarditis, pancreatitis, and pulmonary edema.[24]
- Some studies indicate that coxsackievirus infections may also be associated with spontaneous abortions.[25]
Complications
Pneumonia, myocarditis, pancreatitis, and pulmonary edema, as well as serositis involving other major organs, are rarely associated with HFMD.[24] A large meta-analysis of children with HFMD suggested that lethargy, pneumo-edema/pneumorrhagia, seizures, dyspnoea, and coma were risk factors for death in HFMD.[26] The case fatality rate associated with enterovirus 71 was 1.7% in a systematic review and meta-analysis.[27]
Deterrence and Patient Education
Patient/parental education is paramount in reducing the transmission of HFMD among children and also between children and adults. Handwashing has been proven to be an effective strategy in the prevention of HFMD transmission.[28] A community intervention study showed that intensive education on hand hygiene improved the personal hygiene of parents and children. This subsequently reduced the incidence of HFMD in the study population.[29] The parents should also be advised to keep the child away from immunosuppressed individuals due to the potential risk of serious illness.
Pearls and Other Issues
The majority of patients with coxsackievirus-induced HFMD are treated as outpatients, but those who have central nervous system involvement may require admission for close monitoring. These patients often require imaging studies of the brain to guide treatment and recovery. Infants may develop dehydration, especially if they develop painful oral ulcers and require Intravenous hydration. Admission is highly recommended for any infant with HFMD who shows signs of severe disease and lethargy. The virus is shed in the stools for a few weeks; hence, patients should be educated about hand washing and maintenance of good personal hygiene.
Enhancing Healthcare Team Outcomes
Cases of HFMD are on the rise, and clinicians need to know how to make the diagnosis. A neurological consult may be necessary because many recent cases have involved the brain. An interprofessional team that includes clinicians (MDs, DOs, NPs, or PAs), specialists (neurologist, pediatrician, internist, infectious disease expert), nursing staff, and a pharmacist should be involved. Clinicians diagnose and initiate therapy and decide which referrals may be necessary. Pharmacists can assist with medication management, perform medication reconciliation, and answer questions about the agents used. Nurses coordinate activities with other interprofessional team members, help with examinations, and counsel patients or parents. Everyone on the team must communicate openly with the rest of the care team to ensure the best care leading to optimal outcomes. The outcomes for most patients with HFMD are excellent, with full recovery occurring within 7 to 21 days.
Media
(Click Image to Enlarge)
References
Woodland DL. Hand, Foot, and Mouth Disease. Viral immunology. 2019 May:32(4):159. doi: 10.1089/vim.2019.29037.dlw. Epub 2019 Apr 30 [PubMed PMID: 31038400]
Zhu L, Yin H, Sun H, Qian T, Zhu J, Qi G, Wang Y, Qi B. The clinical value of aquaporin-4 in children with hand, foot, and mouth disease and the effect of magnesium sulfate on its expression: a prospective randomized clinical trial. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2019 Jul:38(7):1343-1349. doi: 10.1007/s10096-019-03559-2. Epub 2019 Apr 26 [PubMed PMID: 31028503]
Level 2 (mid-level) evidenceWu CY, Lin FL. Hand-foot-and-mouth-disease-induced Koebner phenomenon in psoriasis. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. 2019 May:17(5):549-551. doi: 10.1111/ddg.13824. Epub 2019 Apr 17 [PubMed PMID: 30994243]
Muzumdar S, Rothe MJ, Grant-Kels JM. The rash with maculopapules and fever in children. Clinics in dermatology. 2019 Mar-Apr:37(2):119-128. doi: 10.1016/j.clindermatol.2018.12.005. Epub 2018 Dec 5 [PubMed PMID: 30981292]
Nelson BR, Edinur HA, Abdullah MT. Compendium of hand, foot and mouth disease data in Malaysia from years 2010-2017. Data in brief. 2019 Jun:24():103868. doi: 10.1016/j.dib.2019.103868. Epub 2019 Mar 20 [PubMed PMID: 30976640]
Tsai YH, Huang SW, Hsieh WS, Cheng CK, Chang CF, Wang YF, Wang JR. Enterovirus A71 Containing Codon-Deoptimized VP1 and High-Fidelity Polymerase as Next-Generation Vaccine Candidate. Journal of virology. 2019 Jul 1:93(13):. doi: 10.1128/JVI.02308-18. Epub 2019 Jun 14 [PubMed PMID: 30996087]
Kimmis BD, Downing C, Tyring S. Hand-foot-and-mouth disease caused by coxsackievirus A6 on the rise. Cutis. 2018 Nov:102(5):353-356 [PubMed PMID: 30566537]
Bian L, Gao F, Mao Q, Sun S, Wu X, Liu S, Yang X, Liang Z. Hand, foot, and mouth disease associated with coxsackievirus A10: more serious than it seems. Expert review of anti-infective therapy. 2019 Apr:17(4):233-242. doi: 10.1080/14787210.2019.1585242. Epub 2019 Mar 6 [PubMed PMID: 30793637]
Sarma N. Hand, foot, and mouth disease: current scenario and Indian perspective. Indian journal of dermatology, venereology and leprology. 2013 Mar-Apr:79(2):165-75. doi: 10.4103/0378-6323.107631. Epub [PubMed PMID: 23442455]
Level 3 (low-level) evidenceEsposito S, Principi N. Hand, foot and mouth disease: current knowledge on clinical manifestations, epidemiology, aetiology and prevention. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2018 Mar:37(3):391-398. doi: 10.1007/s10096-018-3206-x. Epub 2018 Feb 6 [PubMed PMID: 29411190]
Nguyen HX, Chu C, Tran QD, Rutherford S, Phung D. Temporal relationships between climate variables and hand-foot-mouth disease: a multi-province study in the Mekong Delta Region, Vietnam. International journal of biometeorology. 2020 Mar:64(3):389-396. doi: 10.1007/s00484-019-01824-9. Epub 2019 Nov 12 [PubMed PMID: 31720856]
Mirand A, Cohen R, Bisseux M, Tomba S, Sellem FC, Gelbert N, Béchet S, Frandji B, Archimbaud C, Brebion A, Chabrolles H, Regagnon C, Levy C, Bailly JL, Henquell C. A large-scale outbreak of hand, foot and mouth disease, France, as at 28 September 2021. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2021 Oct:26(43):. doi: 10.2807/1560-7917.ES.2021.26.43.2100978. Epub [PubMed PMID: 34713796]
Saguil A, Kane SF, Lauters R, Mercado MG. Hand-Foot-and-Mouth Disease: Rapid Evidence Review. American family physician. 2019 Oct 1:100(7):408-414 [PubMed PMID: 31573162]
Broccolo F, Drago F, Ciccarese G, Genoni A, Porro A, Parodi A, Chumakov K, Toniolo A. Possible long-term sequelae in hand, foot, and mouth disease caused by Coxsackievirus A6. Journal of the American Academy of Dermatology. 2019 Mar:80(3):804-806. doi: 10.1016/j.jaad.2018.08.034. Epub 2019 Jan 17 [PubMed PMID: 30661911]
Rasti M, Khanbabaei H, Teimoori A. An update on enterovirus 71 infection and interferon type I response. Reviews in medical virology. 2019 Jan:29(1):e2016. doi: 10.1002/rmv.2016. Epub 2018 Oct 30 [PubMed PMID: 30378208]
Coates SJ, Davis MDP, Andersen LK. Temperature and humidity affect the incidence of hand, foot, and mouth disease: a systematic review of the literature - a report from the International Society of Dermatology Climate Change Committee. International journal of dermatology. 2019 Apr:58(4):388-399. doi: 10.1111/ijd.14188. Epub 2018 Sep 5 [PubMed PMID: 30187452]
Level 1 (high-level) evidenceHe Y, Yang J, Zeng G, Shen T, Fontaine RE, Zhang L, Shi G, Wang Y, Li Q, Long J. Risk factors for critical disease and death from hand, foot and mouth disease. The Pediatric infectious disease journal. 2014 Sep:33(9):966-70. doi: 10.1097/INF.0000000000000319. Epub [PubMed PMID: 24577041]
Level 2 (mid-level) evidenceKim B, Moon S, Bae GR, Lee H, Pai H, Oh SH. Factors associated with severe neurologic complications in patients with either hand-foot-mouth disease or herpangina: A nationwide observational study in South Korea, 2009-2014. PloS one. 2018:13(8):e0201726. doi: 10.1371/journal.pone.0201726. Epub 2018 Aug 10 [PubMed PMID: 30096160]
Level 2 (mid-level) evidenceVelástegui J, Cova L, Galarza Y, Fierro P, León Baryolo L, Bustillos A. [A case report of hand, foot, and mouth disease with necrotizing mucocutaneous lesions]. Medwave. 2019 Aug 14:19(7):e7683. doi: 10.5867/medwave.2019.07.7683. Epub 2019 Aug 14 [PubMed PMID: 31442216]
Level 3 (low-level) evidenceLi JX, Song YF, Wang L, Zhang XF, Hu YS, Hu YM, Xia JL, Li J, Zhu FC. Two-year efficacy and immunogenicity of Sinovac Enterovirus 71 vaccine against hand, foot and mouth disease in children. Expert review of vaccines. 2016:15(1):129-37. doi: 10.1586/14760584.2016.1096782. Epub 2015 Oct 13 [PubMed PMID: 26460695]
Nayak G, Bhuyan SK, Bhuyan R, Sahu A, Kar D, Kuanar A. Global emergence of Enterovirus 71: a systematic review. Beni-Suef University journal of basic and applied sciences. 2022:11(1):78. doi: 10.1186/s43088-022-00258-4. Epub 2022 Jun 13 [PubMed PMID: 35730010]
Level 1 (high-level) evidenceLewis A, Josiowicz A, Hirmas Riade SM, Tous M, Palacios G, Cisterna DM. Introduction and Differential Diagnosis of Monkeypox in Argentina, 2022. Emerging infectious diseases. 2022 Oct:28(10):2123-2125. doi: 10.3201/eid2810.221075. Epub 2022 Aug 12 [PubMed PMID: 35960545]
Level 3 (low-level) evidenceGonzalez G, Carr MJ, Kobayashi M, Hanaoka N, Fujimoto T. Enterovirus-Associated Hand-Foot and Mouth Disease and Neurological Complications in Japan and the Rest of the World. International journal of molecular sciences. 2019 Oct 20:20(20):. doi: 10.3390/ijms20205201. Epub 2019 Oct 20 [PubMed PMID: 31635198]
Park B, Kwon H, Lee K, Kang M. Acute pancreatitis in hand, foot and mouth disease caused by Coxsackievirus A16: case report. Korean journal of pediatrics. 2017 Oct:60(10):333-336. doi: 10.3345/kjp.2017.60.10.333. Epub 2017 Oct 20 [PubMed PMID: 29158768]
Level 3 (low-level) evidenceOgilvie MM, Tearne CF. Spontaneous abortion after hand-foot-and-mouth disease caused by Coxsackie virus A16. British medical journal. 1980 Dec 6:281(6254):1527-8 [PubMed PMID: 6254606]
Level 3 (low-level) evidenceNi XF, Li X, Xu C, Xiong Q, Xie BY, Wang LH, Peng YH, Li XW. Risk factors for death from hand-foot-mouth disease: a meta-analysis. Epidemiology and infection. 2020 Feb 27:148():e44. doi: 10.1017/S0950268819002279. Epub 2020 Feb 27 [PubMed PMID: 32102711]
Level 1 (high-level) evidenceZhao YY, Jin H, Zhang XF, Wang B. Case-fatality of hand, foot and mouth disease associated with EV71: a systematic review and meta-analysis. Epidemiology and infection. 2015 Oct:143(14):3094-102. doi: 10.1017/S095026881500028X. Epub 2015 Feb 27 [PubMed PMID: 25721492]
Level 1 (high-level) evidenceZhang D, Li Z, Zhang W, Guo P, Ma Z, Chen Q, Du S, Peng J, Deng Y, Hao Y. Hand-Washing: The Main Strategy for Avoiding Hand, Foot and Mouth Disease. International journal of environmental research and public health. 2016 Jun 18:13(6):. doi: 10.3390/ijerph13060610. Epub 2016 Jun 18 [PubMed PMID: 27322307]
Guo N, Ma H, Deng J, Ma Y, Huang L, Guo R, Zhang L. Effect of hand washing and personal hygiene on hand food mouth disease: A community intervention study. Medicine. 2018 Dec:97(51):e13144. doi: 10.1097/MD.0000000000013144. Epub [PubMed PMID: 30572426]